Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia
Boehringer Ingelheim and Click Therapeutics today announced that the pivotal Phase III CONVOKE study (NCT05838625) of CT-155 (BI 3972080), an investigational prescription digital therapeutic (PDT), met its primary endpoint. The randomized, double-blind, controlled study investigated the effectiveness and safety of CT-155 versus a digital control app as an adjunct to standard of care antipsychotic therapy […]
Healthcare-Focused Secondaries Manager Revelation Partners Names Rob Rein as Principal and Courtney Munley and Vicky Valverde as Senior Associates
Revelation Partners, a secondaries investor focused exclusively on the private healthcare market, today announced that Rob Rein has been named principal and Courtney Munley and Vicky Valverde have been named senior associates. Rein joined Revelation Partners in June 2023 as a vice president and helps drive the firm’s sourcing and transaction execution efforts. He has supported multiple transactions that provided liquidity to […]
Nordic Capital Acquires Healthcare Analytics Company Arcadia
European investor Nordic Capital has acquired healthcare analytics company Arcadia Solutions to leverage artificial intelligence’s potential to improve healthcare and save money. The Nordic acquisition marks an exit for earlier investors, such as healthcare specialist Peloton Equity, whose predecessor firm Ferrer Freeman acquired Arcadia in 2012. Other backers include drugmaker Merck’s digital-health venture-capital arm and private-credit […]
Bridging the Divide: Building Toward Earlier, Smarter, and More Connected Cancer Care
Disclaimer: Revelation Partners is invested in Carrum Health, Bristol Hospice, Genome Medical, and Metabolon. Fragmented, Costly, and Complex: The State of U.S. Cancer Care Over the past century, we have made remarkable strides in the fight against cancer—from the advent of chemotherapy in the 1940s to today’s targeted, immune, and cell-based therapies that have expanded […]
Revelation-Backed Omada Health Jumps After $150 Million IPO
Omada Health Inc. shares climbed 21% in their trading debut after the digital health-care company raised $150 million in its initial public offering. The stock opened at $23 on Friday in New York, higher than its IPO price of $19 per share. The San Francisco-based company sold 7.9 million shares at $19 each after offering them at $18 to $20 […]
Fuze Health Launches to Transform Patient Experiences and Enable Personalized Care in a Changing Healthcare Environment
Fuze Health, a technology-powered healthcare solutions company committed to transforming patient experiences and advancing personalized care, launched today. The company is focused on enabling healthcare partners – including care providers, employers, health plans and life sciences companies – to excel in an outcomes-focused system and empowering patients to more comprehensively manage their health at home. […]
Beyond the Drug: Investment Opportunities in the Growing GLP-1 Market
In this white paper, we cover:
Venture Secondary Summit 2025: Key takeaways
The inaugural Venture Secondary Summit, held in California from April 1–2, convened leadingvoices from across the venture capital secondaries ecosystem. The two-day event featured arange of discussions—from market sizing and structural innovation, to growth expectations anddifferentiation strategies—drawing participation from firms including Jefferies, Kline Hill,Lazard, Campbell Lutyens, StepStone Group, Goldman Sachs, and more. To glean further […]
Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States
Click Therapeutics, Inc., (“Click”) a leader in prescription medical treatments as both prescription digital therapeutics and software-enhanced drug™ therapies, has obtained FDA marketing authorization for the first prescription digital therapeutic for the preventive treatment of episodic migraine. FDA granted the De Novo Classification Request for the company’s prescription digital therapeutic, CT-132, for the preventive treatment […]
Summit Spine Expands with a Unique Physician-Centric Model in Interventional Spine Care
Summit Spine & Joint Centers (“Summit”), a leading minimally invasive spinal services platform, is revolutionizing the field with a distinctive structure that combines hospital affiliations, and Ambulatory Surgery Center (ASC) ownership opportunities for physicians. This innovative model has been the driving force behind the company’s sustained growth over the past ten years. Summit completed a recapitalization with […]